BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20180311T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20181104T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191027T080000
DTEND;TZID=America/New_York:20191101T170000
DTSTAMP:20260714T222908
CREATED:20191023T172823Z
LAST-MODIFIED:20191023T172823Z
UID:27363-1572163200-1572627600@scienceinboston.com
SUMMARY:Leadership Strategies for Evolving Health Care Executives
DESCRIPTION:Overview\n\nHealth Care Executive Leadership Program Overview \nFocusing on management systems specific to health care\, this program provides skill building in the critical areas of leadership and management development. \nThe curriculum is designed to develop conflict resolution\, operational analysis\, employee management\, and quality management techniques necessary to achieve individual and organizational objectives. \nToday’s knowledge base is different from that of even six months ago\, and the solutions to tomorrow’s problems are within reach. \nAs a leader in the continuously evolving field of health care\, you have the formidable and immediate challenge of creating both short- and long-term strategies. This six-day program will enable you to respond proactively to the rapidly changing health care environment. \nProgram Benefits — Why You Should Participate \nGain insight into and develop the skills required to lead effectively in the dynamic and fast-changing field of health care. You will learn from distinguished Harvard faculty and network with professionals from prominent organizations. \nProgram Benefits \n\nSave money by knowing how to purchase services more effectively\nLearn how to decrease costly medical\, patient\, administrative\, and management errors\nBuild teams and processes to reduce redundancy; improving quality and reducing waste\nBenefit from consultant quality insight; improving productivity while increasing morale\n\nCourse Website
URL:https://scienceinboston.com/event/leadership-strategies-for-evolving-health-care-executives-2/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191027T080000
DTEND;TZID=America/New_York:20191101T170000
DTSTAMP:20260714T222908
CREATED:20191023T172823Z
LAST-MODIFIED:20191023T172823Z
UID:6961-1572163200-1572627600@scienceinboston.com
SUMMARY:Leadership Strategies for Evolving Health Care Executives
DESCRIPTION:Overview\n\nHealth Care Executive Leadership Program Overview \nFocusing on management systems specific to health care\, this program provides skill building in the critical areas of leadership and management development. \nThe curriculum is designed to develop conflict resolution\, operational analysis\, employee management\, and quality management techniques necessary to achieve individual and organizational objectives. \nToday’s knowledge base is different from that of even six months ago\, and the solutions to tomorrow’s problems are within reach. \nAs a leader in the continuously evolving field of health care\, you have the formidable and immediate challenge of creating both short- and long-term strategies. This six-day program will enable you to respond proactively to the rapidly changing health care environment. \nProgram Benefits — Why You Should Participate \nGain insight into and develop the skills required to lead effectively in the dynamic and fast-changing field of health care. You will learn from distinguished Harvard faculty and network with professionals from prominent organizations. \nProgram Benefits \n\nSave money by knowing how to purchase services more effectively\nLearn how to decrease costly medical\, patient\, administrative\, and management errors\nBuild teams and processes to reduce redundancy; improving quality and reducing waste\nBenefit from consultant quality insight; improving productivity while increasing morale\n\nCourse Website
URL:https://scienceinboston.com/event/leadership-strategies-for-evolving-health-care-executives/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191101T080000
DTEND;TZID=America/New_York:20191101T170000
DTSTAMP:20260714T222908
CREATED:20191021T131446Z
LAST-MODIFIED:20191021T131446Z
UID:6868-1572595200-1572627600@scienceinboston.com
SUMMARY:Questrom’s Seventh Annual Health & Life Sciences Conference
DESCRIPTION:The Health & Life Sciences Conference is an annual\, student-organized event that brings together a diverse audience of more than 250 students and professionals across all sectors of the US healthcare industry for valuable networking and comprehensive programming spanning healthcare delivery and hospitals\, to pharmaceuticals and medical devices. \n2019 Health & Life Science Conference  \nDisruption in the Face of Limitation:\nInnovation in an Era of Consumerism and Cost Sensitivity \nAs we approach 2020\, healthcare in the United States still occupies a large percentage of the United States Gross Domestic Product. Growing healthcare expenditures remain to be forecast for the coming years. With many industries embracing disruption through innovation\, can healthcare be targeted with initiatives to creatively decrease costs in the face of rising demand? At the 7th Annual Questrom Health & Life Sciences Conference\, panelists and speakers representing diverse stakeholders in the US healthcare system will engage in discussions around topics at the center of this drive to improve value so that we may begin to understand its impact\, both present and promised. \nTo show our appreciation\, our speakers from past years’ conferences are invited to attend this year’s conference as our guests! Please email buhlsc@bu.edu to receive a code for a complimentary conference ticket.
URL:https://scienceinboston.com/event/questroms-seventh-annual-health-life-sciences-conference/
LOCATION:Questrom School of Business\, 595 Commonwealth Ave\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191101T080000
DTEND;TZID=America/New_York:20191101T170000
DTSTAMP:20260714T222908
CREATED:20191021T131446Z
LAST-MODIFIED:20191021T131446Z
UID:27346-1572595200-1572627600@scienceinboston.com
SUMMARY:Questrom’s Seventh Annual Health & Life Sciences Conference
DESCRIPTION:The Health & Life Sciences Conference is an annual\, student-organized event that brings together a diverse audience of more than 250 students and professionals across all sectors of the US healthcare industry for valuable networking and comprehensive programming spanning healthcare delivery and hospitals\, to pharmaceuticals and medical devices. \n2019 Health & Life Science Conference  \nDisruption in the Face of Limitation:\nInnovation in an Era of Consumerism and Cost Sensitivity \nAs we approach 2020\, healthcare in the United States still occupies a large percentage of the United States Gross Domestic Product. Growing healthcare expenditures remain to be forecast for the coming years. With many industries embracing disruption through innovation\, can healthcare be targeted with initiatives to creatively decrease costs in the face of rising demand? At the 7th Annual Questrom Health & Life Sciences Conference\, panelists and speakers representing diverse stakeholders in the US healthcare system will engage in discussions around topics at the center of this drive to improve value so that we may begin to understand its impact\, both present and promised. \nTo show our appreciation\, our speakers from past years’ conferences are invited to attend this year’s conference as our guests! Please email buhlsc@bu.edu to receive a code for a complimentary conference ticket.
URL:https://scienceinboston.com/event/questroms-seventh-annual-health-life-sciences-conference-2/
LOCATION:Questrom School of Business\, 595 Commonwealth Ave\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191101T083000
DTEND;TZID=America/New_York:20191101T180000
DTSTAMP:20260714T222908
CREATED:20191021T131835Z
LAST-MODIFIED:20191021T131835Z
UID:6872-1572597000-1572631200@scienceinboston.com
SUMMARY:Activated Egg Symposium
DESCRIPTION:The Bedford Research Foundation’s Activated Egg Symposium is a world-class lecture symposium featuring thought leaders from around the globe.  This years keynote speakers include: Dr. Joseph Takahashi\, Dr. Shoukhrat Mitalipov\, Dr. Ann A Kiessling and more.  A full lunch and dinner are provided as part of the registration\, the dinner speaker is renowned ethasist Arthur Applbaum.
URL:https://scienceinboston.com/event/activated-egg-symposium/
LOCATION:Marriot Courtyard Boston Downtown\, 275 Tremont St.\, Boston\, MA\, 02116\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191101T083000
DTEND;TZID=America/New_York:20191101T180000
DTSTAMP:20260714T222908
CREATED:20191021T131835Z
LAST-MODIFIED:20191021T131835Z
UID:27347-1572597000-1572631200@scienceinboston.com
SUMMARY:Activated Egg Symposium
DESCRIPTION:The Bedford Research Foundation’s Activated Egg Symposium is a world-class lecture symposium featuring thought leaders from around the globe.  This years keynote speakers include: Dr. Joseph Takahashi\, Dr. Shoukhrat Mitalipov\, Dr. Ann A Kiessling and more.  A full lunch and dinner are provided as part of the registration\, the dinner speaker is renowned ethasist Arthur Applbaum.
URL:https://scienceinboston.com/event/activated-egg-symposium-2/
LOCATION:Marriot Courtyard Boston Downtown\, 275 Tremont St.\, Boston\, MA\, 02116\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191103T080000
DTEND;TZID=America/New_York:20191115T170000
DTSTAMP:20260714T222908
CREATED:20191021T132047Z
LAST-MODIFIED:20191021T132047Z
UID:6876-1572768000-1573837200@scienceinboston.com
SUMMARY:Leadership Development for Physicians in Academic Health Centers
DESCRIPTION:Overview\n\nAcademic health centers in the United States are experiencing major change as a result of the effects of health reform and financial pressures. In addition to the restructuring of the clinical enterprise\, academic centers are being challenged to sustain their academic missions and priorities in the face of resource constraints. In order to tackle these challenges\, institutions need physicians in administrative positions at all levels who can provide leadership and thoughtful managerial initiatives. \nFor over forty years Harvard has conducted intensive two-week executive development programs designed specifically for chairs\, chiefs\, and medical directors in clinical departments at major teaching hospitals. During that time\, leaders from institutions in all regions of the United States have participated in and praised these unique educational programs. \nLeadership Development for Physicians in Academic Health Centers is designed to serve a wide array of physician leaders. It convenes medical directors and chiefs of divisions from academic health centers together with an interdisciplinary faculty team for two weeks of intensive and systematic study of the critical leadership and management issues faced by physicians in administrative positions and academic health centers. \nCurriculum \nThe curriculum is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nFinancial Analysis\nOperations Management\nOrganizational Issues\nConflict Resolution and Negotiation\nLeadership\nHealth Policy\n\nA carefully integrated curriculum permits participants to examine fundamental leadership and managerial issues from the perspective of several disciplines. The overriding purpose for learning concepts\, techniques and skills in any of the management disciplines in this program is to understand their managerial use and limitations. \nTeaching Methods \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at the Harvard Business School. Most of the cases present actual problem situations familiar to physicians in administrative positions at academic health centers. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and empowers the participant to choose a course of action. \nParticipants go through a three-step study process. First\, participants study each case independently. Then they meet in small discussion groups to test their individual analysis against those of their peers. Lastly\, the entire class discusses the case\, with the professor as a catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and between participants and faculty. \nCourse Website
URL:https://scienceinboston.com/event/leadership-development-for-physicians-in-academic-health-centers/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191103T080000
DTEND;TZID=America/New_York:20191115T170000
DTSTAMP:20260714T222908
CREATED:20191021T132047Z
LAST-MODIFIED:20191021T132047Z
UID:27348-1572768000-1573837200@scienceinboston.com
SUMMARY:Leadership Development for Physicians in Academic Health Centers
DESCRIPTION:Overview\n\nAcademic health centers in the United States are experiencing major change as a result of the effects of health reform and financial pressures. In addition to the restructuring of the clinical enterprise\, academic centers are being challenged to sustain their academic missions and priorities in the face of resource constraints. In order to tackle these challenges\, institutions need physicians in administrative positions at all levels who can provide leadership and thoughtful managerial initiatives. \nFor over forty years Harvard has conducted intensive two-week executive development programs designed specifically for chairs\, chiefs\, and medical directors in clinical departments at major teaching hospitals. During that time\, leaders from institutions in all regions of the United States have participated in and praised these unique educational programs. \nLeadership Development for Physicians in Academic Health Centers is designed to serve a wide array of physician leaders. It convenes medical directors and chiefs of divisions from academic health centers together with an interdisciplinary faculty team for two weeks of intensive and systematic study of the critical leadership and management issues faced by physicians in administrative positions and academic health centers. \nCurriculum \nThe curriculum is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nFinancial Analysis\nOperations Management\nOrganizational Issues\nConflict Resolution and Negotiation\nLeadership\nHealth Policy\n\nA carefully integrated curriculum permits participants to examine fundamental leadership and managerial issues from the perspective of several disciplines. The overriding purpose for learning concepts\, techniques and skills in any of the management disciplines in this program is to understand their managerial use and limitations. \nTeaching Methods \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at the Harvard Business School. Most of the cases present actual problem situations familiar to physicians in administrative positions at academic health centers. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and empowers the participant to choose a course of action. \nParticipants go through a three-step study process. First\, participants study each case independently. Then they meet in small discussion groups to test their individual analysis against those of their peers. Lastly\, the entire class discusses the case\, with the professor as a catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and between participants and faculty. \nCourse Website
URL:https://scienceinboston.com/event/leadership-development-for-physicians-in-academic-health-centers-2/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191103T113000
DTEND;TZID=America/New_York:20191103T120000
DTSTAMP:20260714T222908
CREATED:20191021T132418Z
LAST-MODIFIED:20191021T132418Z
UID:6879-1572780600-1572782400@scienceinboston.com
SUMMARY:PurpleStride Boston 2019: Walk with Elstar Therapeutics
DESCRIPTION:Overview\n\nElstar Therapeutics is proud to be a Silver Sponsor for this year’s PurpleStride in Boston. \nPancreatic cancer has the lowest survival rate of all major cancers\, at just 9%. This deadly disease has stolen our best and our brightest\, but it can’t take away our determination. \nOur team has stepped up to Wage Hope at PurpleStride\, the walk to end pancreatic cancer. Will you help us rewrite the future of this disease by making a donation today? \nEvery dollar that you donate ensures that the Pancreatic Cancer Action Network can continue working to create better outcomes for pancreatic cancer patients and their families. By donating to our team\, you are supporting vital efforts to double pancreatic cancer survival by 2020. \nPurple ribbons aren’t enough. Please join us in the fight today. 
URL:https://scienceinboston.com/event/purplestride-boston-2019-walk-with-elstar-therapeutics/
LOCATION:Boston Common – Parkman Bandstand\, 131 Tremont St\, Boston\, MA\, 02111\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191103T113000
DTEND;TZID=America/New_York:20191103T120000
DTSTAMP:20260714T222908
CREATED:20191021T132418Z
LAST-MODIFIED:20191021T132418Z
UID:27349-1572780600-1572782400@scienceinboston.com
SUMMARY:PurpleStride Boston 2019: Walk with Elstar Therapeutics
DESCRIPTION:Overview\n\nElstar Therapeutics is proud to be a Silver Sponsor for this year’s PurpleStride in Boston. \nPancreatic cancer has the lowest survival rate of all major cancers\, at just 9%. This deadly disease has stolen our best and our brightest\, but it can’t take away our determination. \nOur team has stepped up to Wage Hope at PurpleStride\, the walk to end pancreatic cancer. Will you help us rewrite the future of this disease by making a donation today? \nEvery dollar that you donate ensures that the Pancreatic Cancer Action Network can continue working to create better outcomes for pancreatic cancer patients and their families. By donating to our team\, you are supporting vital efforts to double pancreatic cancer survival by 2020. \nPurple ribbons aren’t enough. Please join us in the fight today. 
URL:https://scienceinboston.com/event/purplestride-boston-2019-walk-with-elstar-therapeutics-2/
LOCATION:Boston Common – Parkman Bandstand\, 131 Tremont St\, Boston\, MA\, 02111\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191104T103000
DTEND;TZID=America/New_York:20191104T160000
DTSTAMP:20260714T222908
CREATED:20191021T132702Z
LAST-MODIFIED:20191021T132702Z
UID:27350-1572863400-1572883200@scienceinboston.com
SUMMARY:Manufacturing Novel Biopharmaceuticals: 6 Keys to Success
DESCRIPTION:Overview\n\nCAI is passionate about helping development and clinical stage companies bring their product to market faster. Our custom solutions integrate the elements of product\, process\, quality\, facility\, and people to enable our clients achieve milestones quickly and reliably – while avoiding missteps that can impact patient access to novel\, life-saving therapies. \nWe welcome you to join our global team of experts to explore Manufacturing Novel Biopharmaceutical Products: Six Keys to Success on November 4th at MassBio in Kendall Square. \nMorning Session topics will include: \n\nQuality Systems: Early Adoption as a Competitive Advantage – John Henchion\nQuality by Design: Accelerating Patient Access to Novel Products – Jim Lambert\nFacility Design for Cell and Gene Therapy Products: Best Practices – Bill Deckert\n\nAfternoon Session topics will include \n\nProcess Validation:  Foundation for Product Lifecycle Management – Rusty Morrison\nTechnology Transfer Project Management Best Practices – Beth Haas\nTalent Plan: Growing the Team to Hit Each Milestone – Harry Benson\nPanel Discussion:  Speed to Market – Making it Happen – All speakers\, moderated by Charlie Maher\, Director Process and Manufacturing Technology\n\nCAI will host a networking lunch between sessions and an after-work reception at Catalyst from 4:00pm – 6:30pm. \nRSVP: https://caimassbio.eventbrite.com
URL:https://scienceinboston.com/event/manufacturing-novel-biopharmaceuticals-6-keys-to-success-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191104T103000
DTEND;TZID=America/New_York:20191104T160000
DTSTAMP:20260714T222908
CREATED:20191021T132702Z
LAST-MODIFIED:20191021T132702Z
UID:6883-1572863400-1572883200@scienceinboston.com
SUMMARY:Manufacturing Novel Biopharmaceuticals: 6 Keys to Success
DESCRIPTION:Overview\n\nCAI is passionate about helping development and clinical stage companies bring their product to market faster. Our custom solutions integrate the elements of product\, process\, quality\, facility\, and people to enable our clients achieve milestones quickly and reliably – while avoiding missteps that can impact patient access to novel\, life-saving therapies. \nWe welcome you to join our global team of experts to explore Manufacturing Novel Biopharmaceutical Products: Six Keys to Success on November 4th at MassBio in Kendall Square. \nMorning Session topics will include: \n\nQuality Systems: Early Adoption as a Competitive Advantage – John Henchion\nQuality by Design: Accelerating Patient Access to Novel Products – Jim Lambert\nFacility Design for Cell and Gene Therapy Products: Best Practices – Bill Deckert\n\nAfternoon Session topics will include \n\nProcess Validation:  Foundation for Product Lifecycle Management – Rusty Morrison\nTechnology Transfer Project Management Best Practices – Beth Haas\nTalent Plan: Growing the Team to Hit Each Milestone – Harry Benson\nPanel Discussion:  Speed to Market – Making it Happen – All speakers\, moderated by Charlie Maher\, Director Process and Manufacturing Technology\n\nCAI will host a networking lunch between sessions and an after-work reception at Catalyst from 4:00pm – 6:30pm. \nRSVP: https://caimassbio.eventbrite.com
URL:https://scienceinboston.com/event/manufacturing-novel-biopharmaceuticals-6-keys-to-success/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191104T163000
DTEND;TZID=America/New_York:20191104T190000
DTSTAMP:20260714T222908
CREATED:20191021T133736Z
LAST-MODIFIED:20191021T133736Z
UID:6886-1572885000-1572894000@scienceinboston.com
SUMMARY:Grand Opening: Ipsen Innovation Center / Biolabs
DESCRIPTION:Description\nOn Monday\, November 4\, 2019\, Ipsen invites you to join us as we celebrate the grand opening of the Ipsen Innovation Center | Biolabs. This event will offer an overview of our new collaborative space\, provide an opportunity to meet our resident companies\, and network with friends and colleagues from across the biotech community. \nLocated in Ipsen’s North American Global Hub in Kendall Square\, the Ipsen Innovation Center | Biolabs provides a collaborative space for early-stage life sciences entrepreneurs\, researchers and investors to develop and deliver new therapies for patients\, including those with cancer\, rare diseases and neurological disorders. The Innovation Center is already home to 11 companies with additional companies preparing to move in. \nTo learn more about Ipsen and its Business Development focus\, click here. \nIf you have any questions about the event\, please contact Nick Chang at nchang@macbiocom.com. \nSpace is limited.
URL:https://scienceinboston.com/event/grand-opening-ipsen-innovation-center-biolabs/
LOCATION:Ipsen Cambridge Office\, 650 Kendall St\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191104T163000
DTEND;TZID=America/New_York:20191104T190000
DTSTAMP:20260714T222908
CREATED:20191021T133736Z
LAST-MODIFIED:20191021T133736Z
UID:27351-1572885000-1572894000@scienceinboston.com
SUMMARY:Grand Opening: Ipsen Innovation Center / Biolabs
DESCRIPTION:Description\nOn Monday\, November 4\, 2019\, Ipsen invites you to join us as we celebrate the grand opening of the Ipsen Innovation Center | Biolabs. This event will offer an overview of our new collaborative space\, provide an opportunity to meet our resident companies\, and network with friends and colleagues from across the biotech community. \nLocated in Ipsen’s North American Global Hub in Kendall Square\, the Ipsen Innovation Center | Biolabs provides a collaborative space for early-stage life sciences entrepreneurs\, researchers and investors to develop and deliver new therapies for patients\, including those with cancer\, rare diseases and neurological disorders. The Innovation Center is already home to 11 companies with additional companies preparing to move in. \nTo learn more about Ipsen and its Business Development focus\, click here. \nIf you have any questions about the event\, please contact Nick Chang at nchang@macbiocom.com. \nSpace is limited.
URL:https://scienceinboston.com/event/grand-opening-ipsen-innovation-center-biolabs-2/
LOCATION:Ipsen Cambridge Office\, 650 Kendall St\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T103000
DTEND;TZID=America/New_York:20191105T143000
DTSTAMP:20260714T222908
CREATED:20191021T134627Z
LAST-MODIFIED:20191021T134627Z
UID:6890-1572949800-1572964200@scienceinboston.com
SUMMARY:Mansfield Bio-Incubator's Second Annual Open House
DESCRIPTION:Overview\n\n  \nMansfield Bio-Incubator invites you to attend its second annual Open House on November 5\, 2019 in Mansfield\, Massachusetts. Come join in the fun and see how innovative startup companies are transforming the world with game-changing inventions in life science! \nOver the past year\,  we have added several new exciting startups while our resident companies have been growing and made progress in their research. \nWe are now gearing to expand beyond our 10\,000 sqft space. Up to 1M sqft of the R&D and manufacturing space is planned to house both earlier-stage and mature life science companies. In this way\, we are catalyzing the transformation of the entire 63-acre former glass bottling factory into a 21st century LIfe Science R&D and manufacturing campus. \nSee more information here! \nThis transformation is all due to the cutting edge science and product development going on in the proof of concept laboratories in the incubator.  We have nucleated the life science ecosystem South of Boston and the success is due to you! \nCome see for yourself that the biotechnology supercluster extends along the South of Boston innovation corridor right here to Mansfield\, Massachusetts. Join in the celebration and envision a future for yourself and your company alongside these pioneers. \nYou are invited to celebrate\, connect and launch! Collaborators\, investments and companies are all right here waiting to meet you. If you are working to find a cure for cancer\, detect disease earlier than ever before or treat diseases that have long been neglected\, you will find a home right here at the Mansfield Bio-Incubator. With fourteen (14) life science companies in place already\, the space is nearly filled to capacity\, but there may be an open spot left\, so hurry and hear from the select resident companies themselves of the benefits of being part of the emerging South of Boston innovation ecosystem. \nWe invite you to check our portfolio companies at: https://www.bioinc.org/portfolio/ \nAgenda: \n10:30 am:    Registration\, Networking and Refreshments \n11:00 am-12 noon:   Welcome (Confirmed Speakers): \n\nRuss Yukhananov\, President\, Mansfield Bio-Incubator\n\nPaul Feeney\,  Massachusetts Senator\, Representing Norfolk &Bristol\n\nRobert Coughlin\, President &CEO\, Massachusetts Biotechnology Council\n\nChristopher Gilrein\, Business Development\, Massachusetts Life Science Center\n\nMike Kennealy\, Secretary\, Executive Office of Housing and Economic Development for the Commonwealth of Massachusetts\n\n\n12:00 noon -1 pm:    Company Presentations\n\n\n1 pm-2:30 pm:    Product Demonstrations\, Continued Networking and Celebrating\, and Facility Tours\n\nPresenting companies (confirmed):\nGAMA Therapeutics is developing photodisinfection therapies and devices in combination with antimicrobial photosensitizers \nHilltop Biosciences is helping animals heal faster\, stronger using next generation allogeneic tissue-we make it easier to treat soft tissue injuries \nEightyEight Pharma is tackling the opioid epidemic by providing an innovative  Oppotoxy™ Bottle\, an opioid abuse deterrent packaging platform.
URL:https://scienceinboston.com/event/mansfield-bio-incubators-second-annual-open-house/
LOCATION:Mansfield Bio-Incubator\, 241 Francis Avenue\, Mansfield\, MA\, 02048\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T103000
DTEND;TZID=America/New_York:20191105T143000
DTSTAMP:20260714T222908
CREATED:20191021T134627Z
LAST-MODIFIED:20191021T134627Z
UID:27352-1572949800-1572964200@scienceinboston.com
SUMMARY:Mansfield Bio-Incubator's Second Annual Open House
DESCRIPTION:Overview\n\n  \nMansfield Bio-Incubator invites you to attend its second annual Open House on November 5\, 2019 in Mansfield\, Massachusetts. Come join in the fun and see how innovative startup companies are transforming the world with game-changing inventions in life science! \nOver the past year\,  we have added several new exciting startups while our resident companies have been growing and made progress in their research. \nWe are now gearing to expand beyond our 10\,000 sqft space. Up to 1M sqft of the R&D and manufacturing space is planned to house both earlier-stage and mature life science companies. In this way\, we are catalyzing the transformation of the entire 63-acre former glass bottling factory into a 21st century LIfe Science R&D and manufacturing campus. \nSee more information here! \nThis transformation is all due to the cutting edge science and product development going on in the proof of concept laboratories in the incubator.  We have nucleated the life science ecosystem South of Boston and the success is due to you! \nCome see for yourself that the biotechnology supercluster extends along the South of Boston innovation corridor right here to Mansfield\, Massachusetts. Join in the celebration and envision a future for yourself and your company alongside these pioneers. \nYou are invited to celebrate\, connect and launch! Collaborators\, investments and companies are all right here waiting to meet you. If you are working to find a cure for cancer\, detect disease earlier than ever before or treat diseases that have long been neglected\, you will find a home right here at the Mansfield Bio-Incubator. With fourteen (14) life science companies in place already\, the space is nearly filled to capacity\, but there may be an open spot left\, so hurry and hear from the select resident companies themselves of the benefits of being part of the emerging South of Boston innovation ecosystem. \nWe invite you to check our portfolio companies at: https://www.bioinc.org/portfolio/ \nAgenda: \n10:30 am:    Registration\, Networking and Refreshments \n11:00 am-12 noon:   Welcome (Confirmed Speakers): \n\nRuss Yukhananov\, President\, Mansfield Bio-Incubator\n\nPaul Feeney\,  Massachusetts Senator\, Representing Norfolk &Bristol\n\nRobert Coughlin\, President &CEO\, Massachusetts Biotechnology Council\n\nChristopher Gilrein\, Business Development\, Massachusetts Life Science Center\n\nMike Kennealy\, Secretary\, Executive Office of Housing and Economic Development for the Commonwealth of Massachusetts\n\n\n12:00 noon -1 pm:    Company Presentations\n\n\n1 pm-2:30 pm:    Product Demonstrations\, Continued Networking and Celebrating\, and Facility Tours\n\nPresenting companies (confirmed):\nGAMA Therapeutics is developing photodisinfection therapies and devices in combination with antimicrobial photosensitizers \nHilltop Biosciences is helping animals heal faster\, stronger using next generation allogeneic tissue-we make it easier to treat soft tissue injuries \nEightyEight Pharma is tackling the opioid epidemic by providing an innovative  Oppotoxy™ Bottle\, an opioid abuse deterrent packaging platform.
URL:https://scienceinboston.com/event/mansfield-bio-incubators-second-annual-open-house-2/
LOCATION:Mansfield Bio-Incubator\, 241 Francis Avenue\, Mansfield\, MA\, 02048\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T180000
DTEND;TZID=America/New_York:20191105T200000
DTSTAMP:20260714T222908
CREATED:20191021T134936Z
LAST-MODIFIED:20191021T134936Z
UID:6894-1572976800-1572984000@scienceinboston.com
SUMMARY:Alexion Research: Building a Pipeline to Service Patients with Rare Disease
DESCRIPTION:BioXchange and Alexion Pharmaceuticals Present: Sharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals\n\n\n\n\n\n\nAbout this Event\n\n\n\nThis event is one of two sessions: \nBoston\, MA – November 5th \nNew Haven\, CT – November 12th \nOverview: \nSharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals; will provide an overview of Alexion Pharmaceuticals and the overall company culture. Along with this\, she will go into a deep discussion with regards to the research the company is currently working on within the rare disease space. \nEvent Agenda: \n6:00PM to 7:00PM – Sharon will discuss what Alexion Pharmaceuticals is doing in terms of research in the rare disease space. This will be followed by a short Q&A session with audience. \n7:00PM to 8:00PM – Networking session with light appetizers provided. \n* Registration does not guarantee your admittance into the event due to the high demand expected. We will personally notify those we are able to accommodate for the event. Either way\, please follow us for details on future events. \n** No walk-ins will be admitted. You must RSVP in order to attend. \nMore on the event organizers: \nAbout BioXchange \nBioXchange is a premier life sciences networking organization founded by some of the most networked people in the Boston life sciences hub. Our goal is to help connect companies and individuals within the epicenter of life sciences industry located in Massachusetts through monthly events. Events are typically held in the two largest concentrated areas for life sciences companies: Cambridge and Waltham. These events are setup to cater to all sectors of the industry from scientists\, law firms\, service companies\, staffing firms\, and many others. \nFeel free to reach out to us directly if you have any questions or concerns at bioxchange.boston@gmail.com. \nAbout Alexion Pharmaceuticals \nAlexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery\, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years\, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS)\, anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders\, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition\, the company is developing several mid-to-late-stage therapies\, including a second complement inhibitor\, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies\, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology\, nephrology\, neurology\, and metabolic disorders. Alexion has been named to the Forbes’ list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston\, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.
URL:https://scienceinboston.com/event/alexion-research-building-a-pipeline-to-service-patients-with-rare-disease/
LOCATION:Alexion Pharmaceuticals Inc.\, 121 Seaport Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T180000
DTEND;TZID=America/New_York:20191105T200000
DTSTAMP:20260714T222908
CREATED:20191021T134936Z
LAST-MODIFIED:20191021T134936Z
UID:27353-1572976800-1572984000@scienceinboston.com
SUMMARY:Alexion Research: Building a Pipeline to Service Patients with Rare Disease
DESCRIPTION:BioXchange and Alexion Pharmaceuticals Present: Sharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals\n\n\n\n\n\n\nAbout this Event\n\n\n\nThis event is one of two sessions: \nBoston\, MA – November 5th \nNew Haven\, CT – November 12th \nOverview: \nSharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals; will provide an overview of Alexion Pharmaceuticals and the overall company culture. Along with this\, she will go into a deep discussion with regards to the research the company is currently working on within the rare disease space. \nEvent Agenda: \n6:00PM to 7:00PM – Sharon will discuss what Alexion Pharmaceuticals is doing in terms of research in the rare disease space. This will be followed by a short Q&A session with audience. \n7:00PM to 8:00PM – Networking session with light appetizers provided. \n* Registration does not guarantee your admittance into the event due to the high demand expected. We will personally notify those we are able to accommodate for the event. Either way\, please follow us for details on future events. \n** No walk-ins will be admitted. You must RSVP in order to attend. \nMore on the event organizers: \nAbout BioXchange \nBioXchange is a premier life sciences networking organization founded by some of the most networked people in the Boston life sciences hub. Our goal is to help connect companies and individuals within the epicenter of life sciences industry located in Massachusetts through monthly events. Events are typically held in the two largest concentrated areas for life sciences companies: Cambridge and Waltham. These events are setup to cater to all sectors of the industry from scientists\, law firms\, service companies\, staffing firms\, and many others. \nFeel free to reach out to us directly if you have any questions or concerns at bioxchange.boston@gmail.com. \nAbout Alexion Pharmaceuticals \nAlexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery\, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years\, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS)\, anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders\, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition\, the company is developing several mid-to-late-stage therapies\, including a second complement inhibitor\, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies\, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology\, nephrology\, neurology\, and metabolic disorders. Alexion has been named to the Forbes’ list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston\, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.
URL:https://scienceinboston.com/event/alexion-research-building-a-pipeline-to-service-patients-with-rare-disease-2/
LOCATION:Alexion Pharmaceuticals Inc.\, 121 Seaport Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20191106T080000
DTEND;TZID=America/Vancouver:20191106T163000
DTSTAMP:20260714T222908
CREATED:20191021T135118Z
LAST-MODIFIED:20191021T135118Z
UID:6897-1573027200-1573057800@scienceinboston.com
SUMMARY:Patient Advocacy Summit 2019
DESCRIPTION:One of MassBio’s most popular events of the year\, the Patient Advocacy Summit brings together the patient advocacy community to showcase best practices and cutting-edge examples of how life sciences companies can more fully incorporate the patient voice into the work they do—not just approaching regulatory applications or at commercialization\, but throughout the drug development cycle. \nThis year we’ll explore competing views on what value therapies bring to various stakeholders\, what a cure is worth to patients and society\, how to improve the clinical trial experience for patients\, and more. We will also have a frank discussion about patient access in the era of transformative therapies\, and you’ll hear directly from patients on what this means to them. \nThe program includes panel discussions\, case study presentations(spotlighting industry/patient partnerships)\, an inspirational keynote address\, as well as a networking lunch and cocktail reception. \nSee sponsorship opportunities here\, or contact Laura Rudberg.
URL:https://scienceinboston.com/event/patient-advocacy-summit-2019/
LOCATION:Marriott Boston Cambridge\, 50 Broadway\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20191106T080000
DTEND;TZID=America/Vancouver:20191106T163000
DTSTAMP:20260714T222908
CREATED:20191021T135118Z
LAST-MODIFIED:20191021T135118Z
UID:27354-1573027200-1573057800@scienceinboston.com
SUMMARY:Patient Advocacy Summit 2019
DESCRIPTION:One of MassBio’s most popular events of the year\, the Patient Advocacy Summit brings together the patient advocacy community to showcase best practices and cutting-edge examples of how life sciences companies can more fully incorporate the patient voice into the work they do—not just approaching regulatory applications or at commercialization\, but throughout the drug development cycle. \nThis year we’ll explore competing views on what value therapies bring to various stakeholders\, what a cure is worth to patients and society\, how to improve the clinical trial experience for patients\, and more. We will also have a frank discussion about patient access in the era of transformative therapies\, and you’ll hear directly from patients on what this means to them. \nThe program includes panel discussions\, case study presentations(spotlighting industry/patient partnerships)\, an inspirational keynote address\, as well as a networking lunch and cocktail reception. \nSee sponsorship opportunities here\, or contact Laura Rudberg.
URL:https://scienceinboston.com/event/patient-advocacy-summit-2019-2/
LOCATION:Marriott Boston Cambridge\, 50 Broadway\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191106T080000
DTEND;TZID=America/New_York:20191106T170000
DTSTAMP:20260714T222908
CREATED:20191021T135316Z
LAST-MODIFIED:20191021T135316Z
UID:27355-1573027200-1573059600@scienceinboston.com
SUMMARY:MedTech Entrepreneurs Bootcamp Powered by MassMEDIC
DESCRIPTION:A one-day\, hands-on workshop for medtech\, digital health founders\, brought to you by MassMEDIC\, Ximedica and Ravenoye Group.\n\n\n\n\n\n\nAbout this Event\n\n\nLEARN FROM ACTUAL ENTREPRENEURS\nThe purpose of this one-day boot camp is to educate current and potential founders and entrepreneurs on the best practices of building a medical device company\, through short sessions and personal stories from those who have done it before. \n\nHow to prepare to be and Entrepreneur AND a Founder\nTips on the best way to fund early stage medtech ventures\nStrategies for successful reimbursement strategies in today’s environment\nStrategies on building a human factors plan\nTips on how to pick the right supplier partners\n\nHear personal experiences\, build your investor network\, and gain insight from key industry thought leaders.\nPreliminary Agenda \n9:00: Welcome \n9:30 – 10:15: How to Prepare to be a medtech founder \n10:15 – 10:30 break / networking \n10:30-11:15: What Investors really want to see \n11:15 – 12:00 How to define and accelerate your path from idea to market \n12:00 – 1:00: Lunch / networking \n1:00-1:45: Regulatory\, Clinical Trials\, and Reimbursement Strategy; the good\, the bad\, the ugly \n1:45-2:30: Why you need to build a Human Factors Plan sooner than later \n2:30- 3:00 Supply Chain Management \n3:00: Closing Remarks \nThis event is for founders and members of the start-up community only. We ask that no service providers register for this program.
URL:https://scienceinboston.com/event/medtech-entrepreneurs-bootcamp-powered-by-massmedic-2/
LOCATION:CIC Providence\, 225 Dyer Street\, Providence\, RI\, 02903\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191106T080000
DTEND;TZID=America/New_York:20191106T170000
DTSTAMP:20260714T222908
CREATED:20191021T135316Z
LAST-MODIFIED:20191021T135316Z
UID:6900-1573027200-1573059600@scienceinboston.com
SUMMARY:MedTech Entrepreneurs Bootcamp Powered by MassMEDIC
DESCRIPTION:A one-day\, hands-on workshop for medtech\, digital health founders\, brought to you by MassMEDIC\, Ximedica and Ravenoye Group.\n\n\n\n\n\n\nAbout this Event\n\n\nLEARN FROM ACTUAL ENTREPRENEURS\nThe purpose of this one-day boot camp is to educate current and potential founders and entrepreneurs on the best practices of building a medical device company\, through short sessions and personal stories from those who have done it before. \n\nHow to prepare to be and Entrepreneur AND a Founder\nTips on the best way to fund early stage medtech ventures\nStrategies for successful reimbursement strategies in today’s environment\nStrategies on building a human factors plan\nTips on how to pick the right supplier partners\n\nHear personal experiences\, build your investor network\, and gain insight from key industry thought leaders.\nPreliminary Agenda \n9:00: Welcome \n9:30 – 10:15: How to Prepare to be a medtech founder \n10:15 – 10:30 break / networking \n10:30-11:15: What Investors really want to see \n11:15 – 12:00 How to define and accelerate your path from idea to market \n12:00 – 1:00: Lunch / networking \n1:00-1:45: Regulatory\, Clinical Trials\, and Reimbursement Strategy; the good\, the bad\, the ugly \n1:45-2:30: Why you need to build a Human Factors Plan sooner than later \n2:30- 3:00 Supply Chain Management \n3:00: Closing Remarks \nThis event is for founders and members of the start-up community only. We ask that no service providers register for this program.
URL:https://scienceinboston.com/event/medtech-entrepreneurs-bootcamp-powered-by-massmedic/
LOCATION:CIC Providence\, 225 Dyer Street\, Providence\, RI\, 02903\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191106T090000
DTEND;TZID=America/New_York:20191107T170000
DTSTAMP:20260714T222908
CREATED:20191021T140217Z
LAST-MODIFIED:20191021T140217Z
UID:27356-1573030800-1573146000@scienceinboston.com
SUMMARY:Challenges in Rare Disease Clinical Trials Symposium & East Training
DESCRIPTION:Description\nSince 2011\, the Complex Innovative Trial Design Symposium and East User Training has brought together industry experts\, thought leaders and applied statisticians to discuss innovations in clinical trials and guide the development of the industry’s leading clinical trial design software\, East. \nThis year we’re proud to be partnering with Alexion to share expertise and ideas surrounding the challenges in rare disease clinical trials. \nWe’re excited to share with you the full list of speakers presenting. Click here to learn more about the speakers and access the presentation abstracts. \nDay 1 Symposium \n8:00AM – 9:00AM \nRegistration and Coffee \n9:00AM – 9:15AM \nWelcome from the Scientific Committee \n9:15AM – 10:15AM \nDrug Development in Rare Diseases – Need for Innovation in Statistical Thinking \nKannan Natarajan\, Pfizer \n10:15AM – 11:00AM \nChallenges in Rare Diseases: The PREVENT Trial for NMSOD \nAmy Pace\, Alexion \n11:00AM – 11:45AM \nHistorical Control Borrowing: Overview\, Advancement and New Methodologies \nJianchang Lin\, Takeda \n11:45AM – 12:45PM \nLunch \n12:45PM – 1:15PM \nCytel Innovations/Roadmap \nGeoffrey Grove\, Cytel \n1:15PM – 2:15PM \nTBC \n2:15PM – 3:00PM \nData Monitoring Committees – Behind Closed Doors \nDavid Kerr\, Axio \n3:00PM – 3:15PM \nBreak \n3:15PM – 4:00PM \nThe Use of Natural History Data in Clinical Trials with Rare Diseases \nClare Elkins\, Alexion \n4:00PM – 4:45PM \nUsing Historical Control for Regulatory Approvals in US – A Practical Review Focusing on Diseases in Small Population \nZiliang Li and Chenkun Wang\, Vertex \n4:45PM – 5:00PM \nClosing Remarks \nDay 2: East Software Training with Pantelis Vlachos\, Principal\, Strategic Consulting \n8:00AM – 9:00AM \nBreakfast and Introduction to East \n9:00AM – 10:45AM \nPhase 1 Dose Escalation (ESCALATE) with Cohort Expansion (PROGRAM) \n10:45AM – 11:00AM \nCoffee Break \n11:00AM – 12:00PM \nPhase 2: MCPMod (Design and Analysis) \n12:00PM – 1:00PM \nLunch and Networking \n1:00PM – 2:00PM \nPhase 2/3: Multi-Arm\, Multiple-Stage Designs (MAMS) \n2:00PM – 3:00PM \nPhase 3: Group Sequential Designs (SURVIVAL) \n3:00PM – 3:15PM \nBreak \n3:15PM – 4:15PM \nPhase 3: Adaptive Designs: Sample Size Re-estimation (SURVADAPT) \n4:15PM – 5:00PM \nPhase 3: Adaptive Population Enrichment (ENRICH) \nEmail sean.cronin@cytel.com if you have any questions.
URL:https://scienceinboston.com/event/challenges-in-rare-disease-clinical-trials-symposium-east-training-2/
LOCATION:Alexion Pharmaceuticals Inc.\, 121 Seaport Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191106T090000
DTEND;TZID=America/New_York:20191107T170000
DTSTAMP:20260714T222908
CREATED:20191021T140217Z
LAST-MODIFIED:20191021T140217Z
UID:6904-1573030800-1573146000@scienceinboston.com
SUMMARY:Challenges in Rare Disease Clinical Trials Symposium & East Training
DESCRIPTION:Description\nSince 2011\, the Complex Innovative Trial Design Symposium and East User Training has brought together industry experts\, thought leaders and applied statisticians to discuss innovations in clinical trials and guide the development of the industry’s leading clinical trial design software\, East. \nThis year we’re proud to be partnering with Alexion to share expertise and ideas surrounding the challenges in rare disease clinical trials. \nWe’re excited to share with you the full list of speakers presenting. Click here to learn more about the speakers and access the presentation abstracts. \nDay 1 Symposium \n8:00AM – 9:00AM \nRegistration and Coffee \n9:00AM – 9:15AM \nWelcome from the Scientific Committee \n9:15AM – 10:15AM \nDrug Development in Rare Diseases – Need for Innovation in Statistical Thinking \nKannan Natarajan\, Pfizer \n10:15AM – 11:00AM \nChallenges in Rare Diseases: The PREVENT Trial for NMSOD \nAmy Pace\, Alexion \n11:00AM – 11:45AM \nHistorical Control Borrowing: Overview\, Advancement and New Methodologies \nJianchang Lin\, Takeda \n11:45AM – 12:45PM \nLunch \n12:45PM – 1:15PM \nCytel Innovations/Roadmap \nGeoffrey Grove\, Cytel \n1:15PM – 2:15PM \nTBC \n2:15PM – 3:00PM \nData Monitoring Committees – Behind Closed Doors \nDavid Kerr\, Axio \n3:00PM – 3:15PM \nBreak \n3:15PM – 4:00PM \nThe Use of Natural History Data in Clinical Trials with Rare Diseases \nClare Elkins\, Alexion \n4:00PM – 4:45PM \nUsing Historical Control for Regulatory Approvals in US – A Practical Review Focusing on Diseases in Small Population \nZiliang Li and Chenkun Wang\, Vertex \n4:45PM – 5:00PM \nClosing Remarks \nDay 2: East Software Training with Pantelis Vlachos\, Principal\, Strategic Consulting \n8:00AM – 9:00AM \nBreakfast and Introduction to East \n9:00AM – 10:45AM \nPhase 1 Dose Escalation (ESCALATE) with Cohort Expansion (PROGRAM) \n10:45AM – 11:00AM \nCoffee Break \n11:00AM – 12:00PM \nPhase 2: MCPMod (Design and Analysis) \n12:00PM – 1:00PM \nLunch and Networking \n1:00PM – 2:00PM \nPhase 2/3: Multi-Arm\, Multiple-Stage Designs (MAMS) \n2:00PM – 3:00PM \nPhase 3: Group Sequential Designs (SURVIVAL) \n3:00PM – 3:15PM \nBreak \n3:15PM – 4:15PM \nPhase 3: Adaptive Designs: Sample Size Re-estimation (SURVADAPT) \n4:15PM – 5:00PM \nPhase 3: Adaptive Population Enrichment (ENRICH) \nEmail sean.cronin@cytel.com if you have any questions.
URL:https://scienceinboston.com/event/challenges-in-rare-disease-clinical-trials-symposium-east-training/
LOCATION:Alexion Pharmaceuticals Inc.\, 121 Seaport Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191107T110000
DTEND;TZID=America/New_York:20191107T180000
DTSTAMP:20260714T222908
CREATED:20190816T152142Z
LAST-MODIFIED:20190816T152142Z
UID:27322-1573124400-1573149600@scienceinboston.com
SUMMARY:Discover Brigham
DESCRIPTION:An event to educate and inspire collaboration around innovative science\, technology\, and medicine at Brigham and Women’s Hospital. This event is free and open to the public – all are welcome to attend. \nPlease visit our website for more details: www.discoverbrigham.org.
URL:https://scienceinboston.com/event/discover-brigham-2/
LOCATION:Brigham and Women’s Hospital\, 75 Francis Street\, Boston\, MA\, 02115\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191107T110000
DTEND;TZID=America/New_York:20191107T180000
DTSTAMP:20260714T222908
CREATED:20190816T152142Z
LAST-MODIFIED:20190816T160211Z
UID:6226-1573124400-1573149600@scienceinboston.com
SUMMARY:Discover Brigham
DESCRIPTION:An event to educate and inspire collaboration around innovative science\, technology\, and medicine at Brigham and Women’s Hospital. This event is free and open to the public – all are welcome to attend. \nPlease visit our website for more details: www.discoverbrigham.org.
URL:https://scienceinboston.com/event/discover-brigham/
LOCATION:Brigham and Women’s Hospital\, 75 Francis Street\, Boston\, MA\, 02115\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191112T073000
DTEND;TZID=America/New_York:20191112T103000
DTSTAMP:20260714T222908
CREATED:20191108T230223Z
LAST-MODIFIED:20191108T232338Z
UID:7104-1573543800-1573554600@scienceinboston.com
SUMMARY:Medical Devices\, Market Trends & Opportunities - Educational Breakfast
DESCRIPTION:Please join Greenberg Traurig and Exponent for Medical Devices\, Market Trends & Opportunities – Educational Breakfast on Tuesday\, November 12th\, from 7:30 AM to 10:30 AM at the law firm of Greenberg Traurig located at One International Place\, Suite 2000\, in Boston\, Massachusetts. \nThis educational breakfast will address the trends in the MedTech industry\, identify the opportunities for innovators to develop IP\, examine the energy and power management for medical devices\, and develop understanding on requirements and constraints that originate from patients\, physicians\, and regulatory agencies. \n\n\nAGENDA\n7:30 – 8:00 AM Breakfast and Networking \n8:00 – 9:30 AM Panel Discussion \n\nGeoff DaCosta\nDavid Dykman\nDr. David Borsook\, M.D\nDr. Alexander Margulis\, Ph.D.\n\n9:45 – 10:30 AM Presentations: \n\nQuinn C. Horn\, Ph.D.\, P.E. – Battery Selection for Medical Devices\nSergio Mendoza\, Ph.D. – System Requirements for Battery Powered Medical Devices\n\n\n\nSPEAKERS\nQuinn C. Horn\, Ph.D.\, P.E.\, Principal\, Exponent \nDr. Horn has over 20 years of experience solving complex battery safety problems.  Prior to joining Exponent in 2004\, Dr. Horn led the failure analysis group at Energizer/Eveready Battery Company\, where he conducted failure analysis studies on a wide variety of commercial battery systems including lithium-ion\, lithium-primary\, nickel-metal hydride\, nickel cadmium\, lead-acid\, and alkaline primary cells. He is a Research Affiliate at the Massachusetts Institute of Technology\, where he collaborates with researchers in the Electrochemical Energy Laboratory. \n\n\nDavid Dykeman\, Shareholder\, Greenberg Traurig \nDavid Dykeman\, who co-chairs the firm’s global Life Sciences & Medical Technology Group\, is a registered patent attorney with more than 20 years of experience in patent and intellectual property law. David’s practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients\, with particular experience in life sciences\, medical devices\, robotics\, materials\, and information technology. David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions\, multi-national corporations\, and start-up companies. \n\n\nGeoff DaCosta\, Director of Business Development & Licensing\, Medtronic \nGeoff DaCosta is currently a Director of Business Development and Licensing within the Surgical Innovations business of Medtronic\, where he coordinates strategic partnership and M&A activities. Geoff joined Medtronic in 2015 following its acquisition of Covidien PLC.  He started with Covidien in 2008\, serving in various roles\, including Director of Strategy and Business Development within the Vascular Therapies business. Previously\, he worked in the Transaction Advisory Services group of Ernst & Young\, as well as multiple Boston boutique advisory firms. Geoff holds an MBA from the UCLA Anderson School of Management and a BA in Economics from the University of Pennsylvania. \n\n\nAlex Margulis\, Ph.D.\, Chief Operating Officer\, Mansfield Bio-Incubator \nDr. Margulis is currently leveraging his scientific and business acumen to manage the operations and business development at Mansfield Bio-Incubator. Concurrently\, he is working as a Business Development Manager (New England) in a boutique life science and marketing strategy organization. Previously\, while working at Precision Biosystems where he developed and executed a strategy to increase the sales by 100% within 1 year while managing a team of manufacturer’s representatives. Beforehand\, he worked as a Senior Scientist at BIOARRAY Therapeutics\, where he managed the project to set up a fully functional laboratory 33% ahead of schedule while saving money and developed proof-of-concept assays for the company’s leading diagnostic test. \n\n\nDavid Borsook\, MD\, PhD\, Professor\, Harvard Medical School \nDr. Borsook is a Professor at Harvard Medical School.  He has a background in Neurology (MD) and Neurobiology (PhD) and an interest in transferring new technologies into the biotech space. Aside from research focus\, he had a long clinical involvement in pain medicine at MGH\, including being the Director of Pain Medicine at the institution.  He has published nearly 300 articles in peer reviewed journals. His Research Program – The Center for Pain and the Brain – at  Boston Children’s\, Massachusetts General and McLean Hospitals evaluates brain and nerve markers of pain and analgesics. He has authored a number of patents\, was the Chief Scientific Officer of a Biotech he founded and has licensed IP to industry. \n\n\nSergio Mendoza\, Ph.D.\, Senior Associate\, Exponent \nDr. Mendoza is a system engineer who builds on his controls background to perform multi-level analysis on electrified systems pertaining to different industries including automotive\, medical and consumer electronics. His areas of expertise include optimal design of experiments to minimize the cost of experimentation while maximizing the statistical meaning of the data collected; model-based energy\, power and thermal control of battery powered systems\, and estimation of the lifetime of lithium-ion cells. Furthermore\, Dr. Mendoza applies his extensive knowledge of lithium-ion cells and systems background to conduct Design Failure Mode and Effects Analysis (DFMEA) and safety analyses including Preliminary Hazard Analyses (PHA).
URL:https://scienceinboston.com/event/medical-devices-market-trends-opportunities-educational-breakfast/
LOCATION:Greenberg Traurig\, LLP\, One International Place\, #Suite 2000\, Boston\, MA\, 02110\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191112T073000
DTEND;TZID=America/New_York:20191112T103000
DTSTAMP:20260714T222908
CREATED:20191108T230223Z
LAST-MODIFIED:20191108T230223Z
UID:27368-1573543800-1573554600@scienceinboston.com
SUMMARY:Medical Devices\, Market Trends & Opportunities - Educational Breakfast
DESCRIPTION:Please join Greenberg Traurig and Exponent for Medical Devices\, Market Trends & Opportunities – Educational Breakfast on Tuesday\, November 12th\, from 7:30 AM to 10:30 AM at the law firm of Greenberg Traurig located at One International Place\, Suite 2000\, in Boston\, Massachusetts. \nThis educational breakfast will address the trends in the MedTech industry\, identify the opportunities for innovators to develop IP\, examine the energy and power management for medical devices\, and develop understanding on requirements and constraints that originate from patients\, physicians\, and regulatory agencies. \n\n\nAGENDA\n7:30 – 8:00 AM Breakfast and Networking \n8:00 – 9:30 AM Panel Discussion \n\nGeoff DaCosta\nDavid Dykman\nDr. David Borsook\, M.D\nDr. Alexander Margulis\, Ph.D.\n\n9:45 – 10:30 AM Presentations: \n\nQuinn C. Horn\, Ph.D.\, P.E. – Battery Selection for Medical Devices\nSergio Mendoza\, Ph.D. – System Requirements for Battery Powered Medical Devices\n\n\n\nSPEAKERS\nQuinn C. Horn\, Ph.D.\, P.E.\, Principal\, Exponent \nDr. Horn has over 20 years of experience solving complex battery safety problems.  Prior to joining Exponent in 2004\, Dr. Horn led the failure analysis group at Energizer/Eveready Battery Company\, where he conducted failure analysis studies on a wide variety of commercial battery systems including lithium-ion\, lithium-primary\, nickel-metal hydride\, nickel cadmium\, lead-acid\, and alkaline primary cells. He is a Research Affiliate at the Massachusetts Institute of Technology\, where he collaborates with researchers in the Electrochemical Energy Laboratory. \n\n\nDavid Dykeman\, Shareholder\, Greenberg Traurig \nDavid Dykeman\, who co-chairs the firm’s global Life Sciences & Medical Technology Group\, is a registered patent attorney with more than 20 years of experience in patent and intellectual property law. David’s practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients\, with particular experience in life sciences\, medical devices\, robotics\, materials\, and information technology. David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions\, multi-national corporations\, and start-up companies. \n\n\nGeoff DaCosta\, Director of Business Development & Licensing\, Medtronic \nGeoff DaCosta is currently a Director of Business Development and Licensing within the Surgical Innovations business of Medtronic\, where he coordinates strategic partnership and M&A activities. Geoff joined Medtronic in 2015 following its acquisition of Covidien PLC.  He started with Covidien in 2008\, serving in various roles\, including Director of Strategy and Business Development within the Vascular Therapies business. Previously\, he worked in the Transaction Advisory Services group of Ernst & Young\, as well as multiple Boston boutique advisory firms. Geoff holds an MBA from the UCLA Anderson School of Management and a BA in Economics from the University of Pennsylvania. \n\n\nAlex Margulis\, Ph.D.\, Chief Operating Officer\, Mansfield Bio-Incubator \nDr. Margulis is currently leveraging his scientific and business acumen to manage the operations and business development at Mansfield Bio-Incubator. Concurrently\, he is working as a Business Development Manager (New England) in a boutique life science and marketing strategy organization. Previously\, while working at Precision Biosystems where he developed and executed a strategy to increase the sales by 100% within 1 year while managing a team of manufacturer’s representatives. Beforehand\, he worked as a Senior Scientist at BIOARRAY Therapeutics\, where he managed the project to set up a fully functional laboratory 33% ahead of schedule while saving money and developed proof-of-concept assays for the company’s leading diagnostic test. \n\n\nDavid Borsook\, MD\, PhD\, Professor\, Harvard Medical School \nDr. Borsook is a Professor at Harvard Medical School.  He has a background in Neurology (MD) and Neurobiology (PhD) and an interest in transferring new technologies into the biotech space. Aside from research focus\, he had a long clinical involvement in pain medicine at MGH\, including being the Director of Pain Medicine at the institution.  He has published nearly 300 articles in peer reviewed journals. His Research Program – The Center for Pain and the Brain – at  Boston Children’s\, Massachusetts General and McLean Hospitals evaluates brain and nerve markers of pain and analgesics. He has authored a number of patents\, was the Chief Scientific Officer of a Biotech he founded and has licensed IP to industry. \n\n\nSergio Mendoza\, Ph.D.\, Senior Associate\, Exponent \nDr. Mendoza is a system engineer who builds on his controls background to perform multi-level analysis on electrified systems pertaining to different industries including automotive\, medical and consumer electronics. His areas of expertise include optimal design of experiments to minimize the cost of experimentation while maximizing the statistical meaning of the data collected; model-based energy\, power and thermal control of battery powered systems\, and estimation of the lifetime of lithium-ion cells. Furthermore\, Dr. Mendoza applies his extensive knowledge of lithium-ion cells and systems background to conduct Design Failure Mode and Effects Analysis (DFMEA) and safety analyses including Preliminary Hazard Analyses (PHA).
URL:https://scienceinboston.com/event/medical-devices-market-trends-opportunities-educational-breakfast-2/
LOCATION:Greenberg Traurig\, LLP\, One International Place\, #Suite 2000\, Boston\, MA\, 02110\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191112T080000
DTEND;TZID=America/New_York:20191112T170000
DTSTAMP:20260714T222908
CREATED:20191108T231301Z
LAST-MODIFIED:20191108T232235Z
UID:7108-1573545600-1573578000@scienceinboston.com
SUMMARY:New Biotech Funding Models: Is The Tech Revolution Coming?
DESCRIPTION:Early-stage financing and company creation models have evolved significantly over the last two decades from heavily-funded\, brick & mortar\, do or die entities to angel-enabled\, virtual and minimalistic proof of concept start-ups with hand-selected management and externally-enabled resources and ecosystems. Indeed\, the Funding Model for emerging biotech companies appears to borrow from the tech company funding models from two decades prior\, including incubators and accelerators\, angel investors\, shared laboratory and clinical facilities\, “venture engineering” and shared resource programs. At this MassBio program\, under the auspices of Entrepreneurs University\, we will explore the current funding models in vogue today\, the investor landscape\, the impact of advancing science and technology\, new types of partnerships\, and the novel approaches early-stage companies are executing to advance to the next stage of existence – and funding round. Finally\, our panel will provide their ideas on the future of venture funding and early-stage funding models in the biotech industry\, and open the program to a lively discussion with the audience. Our moderator for this program is the inimitable\, ever-effervescent John Hession. Please join us. \nSponsored by the MassBio Entrepreneurs University Working group.
URL:https://scienceinboston.com/event/new-biotech-funding-models-is-the-tech-revolution-coming/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191112T080000
DTEND;TZID=America/New_York:20191112T170000
DTSTAMP:20260714T222908
CREATED:20191108T231301Z
LAST-MODIFIED:20191108T231301Z
UID:27369-1573545600-1573578000@scienceinboston.com
SUMMARY:New Biotech Funding Models: Is The Tech Revolution Coming?
DESCRIPTION:Early-stage financing and company creation models have evolved significantly over the last two decades from heavily-funded\, brick & mortar\, do or die entities to angel-enabled\, virtual and minimalistic proof of concept start-ups with hand-selected management and externally-enabled resources and ecosystems. Indeed\, the Funding Model for emerging biotech companies appears to borrow from the tech company funding models from two decades prior\, including incubators and accelerators\, angel investors\, shared laboratory and clinical facilities\, “venture engineering” and shared resource programs. At this MassBio program\, under the auspices of Entrepreneurs University\, we will explore the current funding models in vogue today\, the investor landscape\, the impact of advancing science and technology\, new types of partnerships\, and the novel approaches early-stage companies are executing to advance to the next stage of existence – and funding round. Finally\, our panel will provide their ideas on the future of venture funding and early-stage funding models in the biotech industry\, and open the program to a lively discussion with the audience. Our moderator for this program is the inimitable\, ever-effervescent John Hession. Please join us. \nSponsored by the MassBio Entrepreneurs University Working group.
URL:https://scienceinboston.com/event/new-biotech-funding-models-is-the-tech-revolution-coming-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
END:VCALENDAR